Literature DB >> 18478155

Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.

Silvano Bertelloni1, Dick Mul.   

Abstract

In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety. In the present paper, recent advances of CPP management with GnRH analogs in men are summarized. End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men. The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478155     DOI: 10.1111/j.1745-7262.2008.00409.x

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  4 in total

1.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

2.  Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.

Authors:  Young Suk Shim; Kyung In Lim; Hae Sang Lee; Jin Soon Hwang
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

3.  Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.

Authors:  Katherine A Lewis; Erica A Eugster
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

Review 4.  The Role of Pediatric Nutrition as a Modifiable Risk Factor for Precocious Puberty.

Authors:  Valeria Calcaterra; Elvira Verduci; Vittoria Carlotta Magenes; Martina Chiara Pascuzzi; Virginia Rossi; Arianna Sangiorgio; Alessandra Bosetti; Gianvincenzo Zuccotti; Chiara Mameli
Journal:  Life (Basel)       Date:  2021-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.